Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changli Wei

Showing results (21-30 of 79) with videos related to

Pageof 8
Sort By:
BMC Nephrology|December 19, 2018
Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximabNada Alachkar, Jing Li, Dany Matar, et al.
Journal of Cellular Physiology|October 21, 2018
Runx2 is required for postnatal intervertebral disc tissue growth and developmentLifan Liao, Hua Jiang, Yunshan Fan, et al.
The Science of the Total Environment|May 25, 2024
Natural background levels, source apportionment and health risks of potentially toxic elements in groundwater of highly urbanized areaYunhui Zhang, Yuting Yan, Rongwen Yao, et al.
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia|October 4, 2013
CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutationGabriel Cara-Fuentes, Carlos Araya, Changli Wei, et al.
Pediatric Nephrology (Berlin, Germany)|November 23, 2013
CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significanceGabriel Cara-Fuentes, Changli Wei, Alfons Segarra, et al.
Pediatric Nephrology (Berlin, Germany)|September 21, 2014
Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosisEduardo H Garin, Jochen Reiser, Gabriel Cara-Fuentes, et al.
Frontiers in Medicine|April 9, 2015
A case report of adrenocorticotropic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoringSiddiq Anwar, Derek S Larson, Nima Naimi, et al.
Journal of Molecular Medicine (Berlin, Germany)|September 28, 2012
The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injuryBin Zhang, Wei Shi, Juan Ma, et al.
Scientific Reports|October 5, 2018
Kidney-derived c-kit<sup>+</sup> progenitor/stem cells contribute to podocyte recovery in a model of acute proteinuriaErika B Rangel, Samirah A Gomes, Rosemeire Kanashiro-Takeuchi, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 13, 2017
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on HemodialysisChristiane Drechsler, Salim S Hayek, Changli Wei, et al.
Pageof 8

Showing results (21-30 of 79) with videos related to

Sort By:
Pageof 8
BMC Nephrology|December 19, 2018
Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximabNada Alachkar, Jing Li, Dany Matar, et al.
Journal of Cellular Physiology|October 21, 2018
Runx2 is required for postnatal intervertebral disc tissue growth and developmentLifan Liao, Hua Jiang, Yunshan Fan, et al.
The Science of the Total Environment|May 25, 2024
Natural background levels, source apportionment and health risks of potentially toxic elements in groundwater of highly urbanized areaYunhui Zhang, Yuting Yan, Rongwen Yao, et al.
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia|October 4, 2013
CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutationGabriel Cara-Fuentes, Carlos Araya, Changli Wei, et al.
Pediatric Nephrology (Berlin, Germany)|November 23, 2013
CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significanceGabriel Cara-Fuentes, Changli Wei, Alfons Segarra, et al.
Pediatric Nephrology (Berlin, Germany)|September 21, 2014
Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosisEduardo H Garin, Jochen Reiser, Gabriel Cara-Fuentes, et al.
Frontiers in Medicine|April 9, 2015
A case report of adrenocorticotropic hormone to treat recurrent focal segmental glomerular sclerosis post-transplantation and biomarker monitoringSiddiq Anwar, Derek S Larson, Nima Naimi, et al.
Journal of Molecular Medicine (Berlin, Germany)|September 28, 2012
The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injuryBin Zhang, Wei Shi, Juan Ma, et al.
Scientific Reports|October 5, 2018
Kidney-derived c-kit<sup>+</sup> progenitor/stem cells contribute to podocyte recovery in a model of acute proteinuriaErika B Rangel, Samirah A Gomes, Rosemeire Kanashiro-Takeuchi, et al.
Clinical Journal of the American Society of Nephrology : CJASN|May 13, 2017
Soluble Urokinase Plasminogen Activator Receptor and Outcomes in Patients with Diabetes on HemodialysisChristiane Drechsler, Salim S Hayek, Changli Wei, et al.
Pageof 8